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Abstract
Background Previous studies have examined changes in plasma markers of inflammation and oxidative stress up to 24 months
following bariatric surgery, but there is limited evidence on the long-term effects of bariatric surgery.
Objectives To examine the effects of bariatric surgery on adipokines (adiponectin, leptin), inflammatory cytokines [C-reactive
protein (CRP), interleukin-6 (IL-6), interleukin-10(IL-10)] and global plasma measures of oxidative stress [thiobarbituric acid
reactive substances (TBARS) and total antioxidant status (TAOS) 1 and 6 months, and 4 years post-surgery in subjects with
obesity and impaired glucose regulation.
Methods A prospective study comprising of 19 participants (13 females, mean age 50.4 ± 6.2 years, mean body mass index
(BMI) 54 ± 14 kg/m2, 17 type 2 diabetes) undergoing bariatric surgery (10 sleeve gastrectomy, 6 biliopancreatic diversion, 2
Roux-en-Y gastric bypass and 1 laparoscopic adjustable gastric banding). Serial measurements of the above markers were made
pre-operatively, 1 and 6 months and 4 years post-operatively.
Results Compared to pre-operative levels, significant decreases were seen 4 years post-operatively in CRP (11.4 vs 2.8 ng/mL,
p < 0.001), IL-6 (8.0 vs 2.1 pg/mL, p < 0.001) and leptin (60.7 vs 32.1 pg/mL, p = 0.001). At 4 years, both fasting and 120 min
TAOS significantly increased by 35% and 19% respectively. However, fasting and 120 min TBARS did not show any significant
changes.
Conclusion To our knowledge, no other studies have described changes in inflammation and oxidative stress at 4 years following
bariatric surgery. This study contributes to the current literature supporting the longer-term beneficial effect of bariatric surgery on
chronic inflammation and oxidative stress.
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Introduction
Chronic systemic inflammation and increased oxidative stress
play a role in the pathogenesis of obesity, type 2 diabetes
(T2DM) and cardiovascular disease [1]. Plasma levels of
adipokines such as adiponectin and leptin and inflammatory
cytokines such as C-reactive protein (CRP), interleukin-6 (IL-
6), interleukin-10 (IL-10) and tumour necrosis factor alpha
(TNF-α) are influenced by adipose tissue mass [2, 3].
Bariatric surgery leads to a significant reduction in adipose
tissue mass and subsequent improvement in systemic inflam-
mation [4].
With respect to oxidative stress, there are conflicting re-
ports in the available literature. Catoi et al. observed no
change in global measures of oxidative stress; nitrite and
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nitrate (NOx), total oxidant status (TOS), total antioxidant
response (TAR), and oxidative stress index (OSI), 6 months
after sleeve gastrectomy (SG) [5]. However, Cabrera et al.
demonstrated that plasma level of glutathione (GSH) and total
radical antioxidant parameter (TRAP) was increased and plas-
ma leve l s o f supe rox ide d i smutase (SOD) and
malondialdehyde (MDA) were decreased in 20 patients with
obesity 12 months after Roux-en-Y Gastric Bypass (RYGB)
[6]. It is important to note that in most of the published studies
examining inflammation or oxidative stress, the follow-up pe-
riod was up to 2 years. There is limited literature available on
the long-term effect of bariatric surgery on inflammation and
no literature available on long-term effect of bariatric surgery
on oxidative stress.
Our previous work demonstrated that SG was associated
with improvement in inflammation and oxidative stress in 55
participants with impaired glucose regulation [7]. The primary
aim of the current study was to examine the long-term
(4 years) effects of bariatric surgery on adipokines
(adiponectin, leptin), inflammatory cytokines (CRP, IL-6,
IL-10) and global plasma measures of oxidative stress (thio-
barbituric acid reactive substances [TBARS] and total antiox-
idant status [TAOS]) regardless of operation types. The sec-
ondary aim was to investigate changes in adipokines
(adiponectin, leptin), inflammatory cytokines (CRP, IL-6,
IL-10) and global plasma measures of oxidative stress at
4 years in the SG group.
Methods
Study Participants
Approval for the study was obtained from the Local
Research Ethics Committee (LREC reference 06/
WMW02/7). Participants (n = 49) who took part in a pre-
viously published initial study (pre-operatively and
followed 1- and 6-month post-operatively) were invited
(by post, email or telephone call) to return at a median
follow-up of 4 years (range 2–7 years). Of these, 19
agreed to participate. Twenty-four potential participants
had relocated, declined or were not contactable, and 6
other potential participants were deceased. The study sam-
ple has been previously described [8]. In brief, the inclu-
sion criteria at the outset of the previous study included
males and females aged between 20 and 60 years with a
body mass index (BMI) ≥ 40 kg/m2. All participants had
previously diagnosed T2DM or diagnosed during an oral
glucose tolerance test (OGTT) at the start of study, or
impaired glucose regulation according to the American
Diabetes Association (ADA) criteria [9]. Buse’s consen-
sus (2009) criteria were used to define diabetes remission
[10].
Study Design
All participants underwent a standardised 75 g OGTT (122
mls of Polycal 61.9 g/100 ml of glucose, Nutricia Clinical
Care, Trowbridge, UK) pre-operatively and at 1 month,
6 months and 4 years post-operatively. All participants were
asked to fast from midnight before the test and all diabetes
related medications were omitted for 24 h before the OGTT.
Plasma samples for adiponectin, leptin, CRP, IL-6 and IL-10
were collected in the fasted state prior to the OGTT and sam-
ples for the measurement of TBARS and TAOS were collect-
ed in the fasted state and at 120 min afterwards. All samples
were collected on ice, centrifuged within 1 h of collection and
stored at − 80 °C until analysis. At the time of each OGTT,
clinical and biochemical information were also obtained.
Clinical measurements included weight, height, BMI, waist
circumference and blood pressure. Biochemical data such as
HbA1c and lipid profile were analysed within the local hos-
pital accredited laboratory. Insulin was measured using an
Invitron Insulin ELISA kit and C-peptide with an Invitron
C-peptide luminescent kit. Insulin resistance and sensitivity
were measured with Homeostasis Model Assessment
(HOMA-2 model) by using measurements of fasting glucose
and C-peptide concentrations [11]. These were calculated by
using the Oxford University online calculator (https://www.
dtu.ox.ac.uk/homacalculator/).
Measurement of Inflammatory Cytokines
Plasma levels of adiponectin, leptin, CRP, IL-6 and IL-10
were measured with R&D Systems Quantikine ELISA kits.
The intra- and inter-assay coefficients of variation of these
immunoassays were as follows: adiponectin 4.7% and 6.9%,
leptin 3.3% and 5.4%, CRP 8.3% and 7.0%, IL-6 4.2% and
6.4% and IL-10 5.0% and 7.5%.
Measurement of Plasma TBARS and TAOS
MDA concentration, as a product of lipid peroxidation, was
measured using a commercially available TBARS Assay
(Cayman Chemical, MI, USA). A higher concentration of
MDA is indicative of higher levels of lipid peroxidation, and
therefore, higher oxidative stress within the sample. Intra- and
inter-assay variability coefficients were 5.2% and 16.2% re-
spectively. Plasma TAOS, which is inversely related to oxida-
tive stress, was measured by Sampson’s modification of
Laight’s photometric microassay [12]. Previous literature
showed that plasma TAOS has a good correlation with plasma
F2-isoprostanes [13]. The TAOS of plasma was determined
by its capacity to inhibit the peroxidase-mediated formation of
the 2,2-azino-bis-3-ethylbensthiazoline-6-sulfonic acid
(ABTS+) radical. The difference in absorbance (control [sa-
line] minus test [plasma]) divided by the control absorbance
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(expressed as a percentage) was used to represent the percent-
age inhibition of the reaction. Intra- and inter-assay variability
coefficients were 4.3% and 10.1% respectively. Since ROS
are highly reactive, they are difficult to measure in any bio-
logical sample, especially in easily accessible specimens such
as serum or plasma. There are controversial views on whether
oxidative stress measurements should be performed in a static
fasting sample or following a dynamic testing such as with a
glucose load [14]. Measuring plasma levels in the presence of
a pro-oxidant stimulus such as glucose may provide a better
measure of the dynamic response within an ex-vivo sample
[15].
Statistical Analysis
Statistical analysis was performed using SPSS (Version
22, SPSS Inc., Chicago). The normality of data was
assessed by the Shapiro-Wilk test. Continuous data with
a normal distribution are presented as mean and standard
deviation, and data that did not have a normal distribution
are described with the median and interquartile range. Log
transformation of data was done where appropriate. We
used ANOVA with post hoc analyses for data with a nor-
mal distribution and Friedman test for data without a nor-
mal distribution. The Pearson’s (normal distribution) cor-
relation and the Spearman’s (non-parametric) correlation
were used. In all cases, p < 0.05 was considered to be
statistically significant.
Results
Participants’ Characteristics
Nineteen participants (13 females) with a mean age of 50.4 ±
6.2 years were included in the analysis. Of the 19 participants,
17 (89.5%) had T2DM and two had impaired fasting glucose
(IFG) pre-operatively. The mean duration of T2DMwas 37.7
± 35.1 months. Ten underwent SG, 6 biliopancreatic diversion
(BPD), 2 RYGB and 1 laparoscopic adjustable gastric banding
(LAGB). The baseline characteristics along with the changes
in anthropometric and clinical measures are summarised in
Table 1. A significant decrease in body weight and BMI were
observed 6 months [(43.2 ± 19.0% excess weight loss (EWL)]
post-operatively and this was maintained at 4 years (43.7 ±
24.5 %EWL). Along with this, a significant decrease in dia-
stolic blood pressure and a significant increase in HDL-C
were observed. HbA1c also showed a significant reduction
of 12 mmol/mol (20.7%) from baseline and 3 out of 17 sub-
jects (17.6%) had achieved complete diabetes remission at
4 years.
Changes in Adipokines and Inflammatory Cytokines
Table 2 shows temporal changes in adipokines and in-
flammatory cytokines. At 4 years, adiponectin did not
show any change compared to the pre-operative levels.
Plasma leptin concentration showed a linear decrease
from 60.7 pg/mL pre-operatively to 40.4 pg/mL at
1 month, 33.7 pg/mL at 6 months and 32.1 pg/mL at
4 years (p = 0.001). The median plasma CRP concentra-
tion decreased from 11.4 ng/mL pre-operative to 3.7 ng/
mL at 1 month, 5.8 ng/mL at 6 months and 2.8 ng/mL at
4 years (p = 0.003). IL-6 was significantly decreased at
4 years compared to the pre-operative value (73.8% de-
crease, p = 0.009). However, IL-10 levels did not show
any significant change compared to the pre-operative
levels.
Changes in Plasma Markers of Oxidative Stress
A non-significant increase in fasting TBARS, and no
change in 120-min TBARS were noted at 4 years com-
pared to the baseline pre-operative values (Table 2). A
non-significant reduction in fasting and 120-min TBARS
was observed at both 1 and 6 months. Compared to the
pre-operative values, fasting TAOS increased by 35%
(p = 0.011) and 120-min TAOS increased by 19% (p =
0.048) at 4 years after surgery (Table 2).
Correlations Between Changes (Delta Δ)
from Pre-operative to 4 Years Post-operative
in Weight, Glucose, Insulin Resistance, Adipokines,
Inflammatory Cytokines and Markers of Oxidative
Stress
There were significant positive correlations between
Δleptin and Δweight (r = 0.656, p = 0.002), and ΔBMI
(r = 0.734, p = 0.001), suggesting a greater reduction in
weight was associated with a greater reduction in leptin.
Changes in 120-min TAOS had negative correlation with
Δ fasting plasma glucose (FPG) (rs = − 0.66, p = 0.004);
and 120-min TBARS had positive correlation with HbA1c
(r = 0.506, p = 0.045). No other correlations were ob-
served between weight, glucose, insulin resistance,
adiponectin and inflammatory cytokines.
Sub-group Analysis: the SG Group
The SG group had amean age of 52 ± 6 years and ameanBMI
of 48.4 ± 7.2 kg/m2. Changes in clinical measures of obesity,
glucose metabolism and incretin hormones in this cohort were
recently published [16]. In brief, a significant reduction in
weight, BMI and markers of glycaemia and a significant in-
crease in total cholesterol, HDL cholesterol and LDL
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cholesterol were observed at 4 years. There was no significant
change in adiponectin levels but a significant reduction in
leptin by 54% at 4 years compared to baseline (Table 3).
Similarly, CRP decreased by 64% and IL-6 decreased by
84%. With regard to markers of oxidative stress, a significant
increase in fasting TBARS and fasting TAOS but no signifi-
cant changes in 120-min TBARS and TAOS were observed
(Table 3).
Discussion
Bariatric surgery is associated with an improvement in meta-
bolic outcomes and a reduction in cardiovascular risk factors.
It is postulated that this is likely to be related to an improve-
ment in the inflammatory environment as a result of rapid and
substantial weight loss. In line with previously published stud-
ies, which had shorter follow-up duration (6 to 24 months) [4,
Table 1 Changes in weight,
blood pressure, lipid profile and
glycaemic control
Baseline 1 month 6 months 4 years p
Weight (kg) 150 ± 37 132 ± 32 117 ± 29 116 ± 27 < 0.001
BMI (kg/m2) 54 ± 14 48 ± 12 43 ± 11 43 ± 11 < 0.001
%EWL 23.6 ± 10.3 43.2 ± 19.0 43.7 ± 24.5
SBP (mmHg) 137 ± 25 123 ± 15 131 ± 14 129 ± 20 0.021
DBP (mmHg) 81 ± 14 71 ± 10 76 ± 8 73 ± 13 0.001
TC (mmol/L) 4.3 ± 0.8 3.8 ± 1.1 4.2 ± 1.3 4.6 ± 1.3 0.178
LDL (mmol/L) 2.3 ± 0.6 2.1 ± 0.9 2.5 ± 1.2 2.4 ± 1.0 0.416
HDL (mmol/L) 1.2 ± 0.3 1.1 ± 0.3 1.2 ± 03 1.5 ± 0.6 0.002
TG (mmol/L) 1.7 ± 0.9 1.5 ± 0.5 1.4 ± 0.5 1.3 ± 0.5 0.151
FPG* (mmol/L) 7.3 (5.9–9.2) 5.7 (4.8–6.8) 5.4 (4.5–6.9) 6.4 (5.5–9.0) 0.378
2 h-PG (mmol/L) 13.1 ± 5.7 8.8 ± 3.8 9.2 ± 6.6 9.4 ± 5.5 0.238
HbA1c (mmol/mol) 58 ± 18 47 ± 12 45 ± 15 46 ± 15 0.049
Fasting insulin* (mU/L) 27.7
(19.6–38.6)
12.6
(7.6–25.6)
10.3
(6.0–20.7)
16.9
(6.0–34.4)
0.135
Fasting C-peptide*
(pmol/ml)
1.4 (0.9–1.6) 1.2 (0.8–1.6) 0.8 (0.6–1.1) 0.5 (0.3–0.7) 0.018
HOMA-%S** 1.6 ± 0.3 1.7 ± 0.3 1.8 ± 0.5 1.8 ± 0.4 0.064
HOMA-IR** 0.4 ± 0.2 0.2 ± 0.3 0.1 ± 0.4 0.2 ± 0.4 0.098
Data are presented as mean ± SD unless otherwise stated.*Data are presented as median and interquartile range.
**Log transformed data. %EWL, percent excess weight loss; SBP, systolic blood pressure; DBP, diastolic blood
pressure; TC, total cholesterol; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein choles-
terol; TG, triglyceride. FPG, fasting plasma glucose; 2 h-PG, 2-h plasma glucose; HbA1c, haemoglobin A1c;
HOMA-%S, homeostatic model assessment (insulin sensitivity); HOMA-IR, homeostatic model assessment (in-
sulin resistance)
p value calculated from ANOVA or Friedman test
Table 2 Changes in adipokines,
inflammatory cytokines and
markers of oxidative stress
Baseline 1 month 6 months 4 years p
Adiponectin* (ng/mL) 8.3 (5.3–10.5) 7.7 (4.0–12.2) 8.2 (4.6–12.1) 6.3 (4.7–13.3) 0.937
Leptin* (pg/mL) 60.7
(32.3–70.3)
40.4
(23.1–62.8)
33.7
(15.6–51.7)
32.1
(15.4–45.7)
0.001
CRP* (ng/mL) 11.4 (3.5–33.0) 3.7 (1.9–19.3) 5.8 (1.9–32.1) 2.8 (1.5–5.7) 0.006
IL-6* (pg/mL) 8.0 (4.2–16.7) 5.6 (3.8–23.3) 11.7 (5.1–24.9) 2.1 (0.9–5.4) 0.005
IL-10* (pg/mL) 7.2 (2.5–9.3) 6.4 (4.9–9.4) 7.1 (5.2–9.4) 5.1 (3.9–8.4) 0.140
Fasting TBARS1
(ng/mL)
44 ± 29 24 ± 16 26 ± 8 63 ± 20 0.388
120-min TBARS2
(ng/mL)
74 ± 41 49 ± 24 43 ± 24 72 ± 24 0.157
Fasting TAOS (%) 38.3 ± 10.8 35.5 ± 9.1 36.3 ± 8.5 51.6 ± 17.2 0.042
120-min TAOS (%) 40.9 ± 7.6 39.4 ± 9.3 33.6 ± 10.8 48.5 ± 13.5 0.026
*Data are presented as median and interquartile range. Data are presented as mean and SD. 1Nine outliers
excluded from analysis. 2 Eight outliers excluded from the analysis. p value calculated from ANOVA or
Friedman test
OBES SURG
8, 17], we observed a significant reduction in pro-
inflammatory biomarkers (leptin, CRP, IL-6) at 4 years.
These improvements were accompanied by an improvement
in body weight (44% EWL), an improvement in glycaemic
control (65% achieving a target HbA1c ≤ 6.5%) and improve-
ments in cardiovascular risk factors (diastolic blood pressure
and HDL-C). However, we observed no significant change in
plasma adiponectin level (but numerical decrease). One pos-
sible explanation for this unexpected finding of plasma
adiponectin level could be type 2 error and the other explana-
tion might be due to small sample size.
Of note, two previous studies have examined changes in
cytokines at 3 years following bariatric surgery. One study
examined CRP, adiponectin, leptin, visfatin, IL-6 and
TNF-α in 10 subjects with normal glucose tolerance follow-
ing BPD. The authors reported that after considerable weight
loss (53% EWL), leptin, CRP and IL-6 decreased but
adiponectin increased significantly. No significant changes
were observed in TNF-α [18]. Another study comprising of
28 subjects with the metabolic syndrome, examined changes
in adipocytokines before and 3, 6, 12 and 24 months after
vertical banded gastrectomy. Of these, six subjects had 36-
and 48-month follow-up. The authors reported a linear in-
crease in levels of adiponectin and resistin along with a non-
significant decrease in CRP at 36 and 48 months, and a sig-
nificant decrease in leptin at 36 months compared to baseline
[19].
In the current study, there was a numerical reduction
(30%) in IL-10 at 4 years compared to baseline.
Although IL-10 is generally regarded as an anti-
inflammatory cytokine, some human experimental studies
revealed pro-inflammatory property of IL-10 [20]. The
published literature contains conflicting reports relating to
the effect of bariatric surgery on IL-10. Netto et al. dem-
onstrated that IL-10 increased by 123 ± 55% (p = 0.02) in
41 subjects with obesity without T2DM, 6 months after
RYGB [21]. Mallipedhi et al. showed no significant chang-
es in IL-10 concentration in 22 patients with T2DM and
impaired glucose regulation 6 months after SG [8].
With respect to oxidative stress, fasting and 120-min TAOS
significantly increased at 4 years compared to the pre-
operative levels. TAOS, a global measure of antioxidant sta-
tus, is inversely associated with oxidative stress and obesity
[22]. Previous work by Prior et al. observed no change in
TAOS in 22 participants with morbid obesity and impaired
glucose regulation 6 months following SG [14]. Two other
studies also reported no changes in plasma TAOS following
surgical induced weight loss. Catoi et al., examined TAOS and
total antioxidant response (TAR) in patients with morbid obe-
sity in comparison with a normal weight control group (n = 23
each group). No significant changes were observed in TAOS
12months after silastic ring vertical gastroplasty [23]. Melissa
et al. described no change in TAOS in 16 subjects with obe-
sity, 6 months following intragastric balloon, despite signifi-
cant reduction in body weight [22].
It is important to note that TAOS can be influenced by
many factors such as age [24], diet [25], vitamin supplemen-
tation [26] and physical activity [27]. Possible explanations
for an increase in TAOS within the current study include
changes in dietary habit following bariatric surgery; vitamin
supplementations following bariatric surgery; possible chang-
es in physical activity due to weight loss; a decrease in pro-
inflammatory cytokines; a better glycaemic control or an im-
provement in cardiovascular risk factors.
Within the current study, no significant change in TBARS
was observed at 4 years, compared to the pre-operative values.
However, we observed an initial decrease (but not statistically
significant) in TBARS at 1 month and 6 months. There are
inconsistent observations on the effect of bariatric surgery on
TBARS. Uzun et al. showed a significant decrease in MDA
and oxidized LDL (ox-LDL) and a strong positive relationship
between MDA and BMI (r = 0.79, p < 0.001) in 20 subjects
with obesity, 6 months after LAGB [28]. Boesing et al. ob-
served that RYGBwas associated with an increase in TBARS,
despite a significant weight loss in 20 subjects at 6 months
[29]. On the other hand, Dadalt et al. (n = 35) described an
initial decrease in TBARS at 12 months after RYGB but this
was not preserved at 24 months, when 25.7% of the partici-
pants regained weight [30].
We observed a positive correlation between Δleptin with
bothΔweight andΔBMI, suggesting a change in weight was
associated with a change in leptin. Leptin is an orexigenic
hormone and high serum leptin concentrations are associated
with high BMI and body fat mass [31]. We also observed a
negative correlation between Δ120-minute TAOS with
ΔFPG and a positive correlation between Δ120 minutes
TBARS with ΔHbA1c. These findings were in agreement
with previous studies describing an association between oxi-
dative stress and markers of glycaemia [32].
Table 3 Adipokines, inflammatory cytokines and markers of oxidative
stress before and 4 years after SG
Baseline 4 years p
Adiponectin (ng/mL) 8.5 (5.8–12.7) 9.1 (5.1–13.3) 0.721
Leptin (pg/mL) 49.1 (30.8–63.9) 27.5 (13.0–44.1) 0.037
CRP (ng/mL) 7.2 (3.2–20.0) 2.6 (1.5–7.6) 0.007
IL-6 (pg/mL) 8.1 (4.9–38.8) 1.3 (0.4–4.6) 0.005
IL-10 (pg/mL) 8.4 (3.5–13.9) 4.9 (3.5–6.5) 0.093
Fasting TBARS (ng/mL) 54 (30–84) 125 (91–208) 0.021
120-min TBARS (ng/mL) 85 (44–132) 93 (80–160) 0.859
Fasting TAOS (%) 38 (47–52) 59 (43–63) 0.038
120-min TAOS (%) 44 (36–46) 50 (32–58) 0.374
Data are presented as median and interquartile range. p value calculated
from Wilcoxon signed rank test
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In the exploratory sub-group analysis, we demonstrated
that SG was associated with a significant reduction in pro-
inflammatory biomarkers (leptin, CRP, IL-6) along with an
improvement in bodyweight and glycaemic control at 4 years.
Our findings were in agreement with previous studies. Zhu
et al. demonstrated a reduction in leptin, CRP and IL-6 in
patients with morbid obesity and subclinical hypothyroidism
12 months following SG [33]. Similarly, Salman et al. dem-
onstrated that the levels of serum adiponectin significantly
increased, while the levels of serum leptin, resistin, CRP, plas-
minogen activator inhibitor-1 and serum amyloid-A signifi-
cantly decreased at 6 months after SG [34]. In contrast to
previous studies [18, 19, 34], we observed no statistically
significant change in serum adiponectin levels. This might
be explained by a small sample size. In our recent published
study comprising 55 participants with impaired glucose regu-
lation, we observed a significant increase in serum
adiponectin level at 6 months following SG [7]. Within the
SG group, there was a significant increase in fasting TBARS
as well as fasting TAOS. Since TBARS is a measure of lipid
peroxidation, an increase in total cholesterol and LDL choles-
terol following SG might explain an increase in fasting
TBARS. Previous studies have shown that SG has no signif-
icant impact on lowering total cholesterol and LDL-C but is
associated with an increase in HDL-C [35–37]. An increase in
TAOS reflects a reduction in global oxidative stress and an
improvement in metabolic profile. Of note, plasma TAOS is
correlated positively with HDL-C and negatively with glucose
and HBA1c [13].
There are limitations to the current study. The first limita-
tion was a small sample size and a considerable drop-out at
4 years. In addition, a considerable number (n = 8) of partici-
pants were excluded for analysis of TBARS due to haemolysis
of blood sample. The second limitation was that the sample
comprised of three participants who had impaired glucose
tolerance, since the level of chronic inflammation and oxida-
tive stress might differ between those with established T2DM.
The third limitation was the accuracy and variability of dura-
tion of diabetes within the group (mean duration 37 ±
35 months) and this might influence the level of inflammatory
makers and oxidative stress pre-operatively. The fourth limi-
tation was that factors influencing antioxidant status such as
diet history, physical activity and uric acid concentrations
were also not recorded. The fifth limitation was the heteroge-
neity of bariatric procedure. However, previous studies dem-
onstrated that weight lost is not dissimilar amongst SG, RYGB
and BPD [38]. Our aim was to examine long-term (4 years)
changes in inflammatory biomarkers and oxidative stress fol-
lowing bariatric surgery irrespective of surgical technique.
Since the SG was the predominate procedure in this cohort,
we also reported sub-group exploratory analysis for the SG
group. To our knowledge, no other studies have described
changes in inflammation and oxidative stress at 4 years
following bariatric surgery. The current study contributes to
the current literature supporting the beneficial effect of bariat-
ric surgery on chronic inflammation and oxidative stress at
4 years. To translate our findings into clinical setting, larger
studies with adequate power and long-term follow-up are
warranted.
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